Acquisition by Zimmermann Martine of 2285 shares of Ligand Pharmaceuticals subject to Rule 16b-3
LGND Stock | USD 116.55 2.09 1.76% |
About 70% of Ligand Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Ligand Pharmaceuticals Incorporated suggests that many traders are alarmed. The current market sentiment, together with Ligand Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Ligand Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Ligand |
Filed transaction by Ligand Pharmaceuticals In director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Ligand Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Ligand Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Ligand Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Ligand Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ligand Pharmaceuticals Historical Investor Sentiment
Investor biases related to Ligand Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ligand. The trend in average sentiment can be used to explain how an investor holding Ligand can time the market purely based on public headlines and social activities around Ligand Pharmaceuticals Incorporated. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ligand Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ligand Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ligand Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Ligand Pharmaceuticals.
Ligand Pharmaceuticals Fundamental Analysis
We analyze Ligand Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ligand Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ligand Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Ligand Pharmaceuticals is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Ligand Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ligand Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Ligand Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ligand Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Ligand Pharmaceuticals Related Equities
PASG | Passage Bio | 6.81 | ||||
ASND | Ascendis Pharma | 2.64 | ||||
LYEL | Lyell Immunopharma | 1.72 | ||||
CRNX | Crinetics Pharmaceuticals | 0.1 | ||||
AKRO | Akero Therapeutics | 0.00 | ||||
ETNB | 89bio | 0.41 | ||||
CYTK | Cytokinetics | 1.02 | ||||
GPCR | Structure Therapeutics | 1.15 | ||||
BPMC | Blueprint Medicines | 1.33 | ||||
RLAY | Relay Therapeutics | 1.54 | ||||
APLS | Apellis Pharmaceuticals | 1.66 | ||||
DSGN | Design Therapeutics | 2.41 | ||||
ORIC | Oric Pharmaceuticals | 3.25 | ||||
VRDN | Viridian Therapeutics | 3.49 | ||||
RCUS | Arcus Biosciences | 3.59 | ||||
CGEM | Cullinan Oncology | 3.83 | ||||
TERN | Terns Pharmaceuticals | 3.88 | ||||
ANNX | Annexon | 4.95 |
Complementary Tools for Ligand Stock analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |